• Busca persones
• Intranet

Redirecció immune Joaquín Arribas

Publicacions 2024 (7)

• Serra-Bardenys G^*, Blanco E, Escudero C, Serra-Camprubi Q, Querol J, Pascual-Reguant L, Morancho B, Escorihuela M, Tissera NS, Sabé A, Martin L, Segura-Bayona S, Verde G, Aiese-Cigliano R, Millanes-Romero A, Jerónimo C, Cebrià JP, Nuciforo P, Simonetti S, Viaplana C, Dienstmann R, Oliveira M, Peg V, Stracker TH, Arribas J, Canals F, Villanueva J, Di Croce L, García de Herreros A, Tian TV^*, Peiró S^*. LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells. FEBS J 2024: (en Premsa).
• de la Fuente-Vivas D, Cappitelli V, García-Gómez R, Valero-Díaz S, Amato C, Rodriguéz J, Duro S, von Kriegsheim A, Grusch M, Lozano J, Arribas J, Casar B^*, Crespo P^*. ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility. Mol Oncol 2024: (en Premsa).
• Román M, Grinyó-Escuer A, Duro S, Rius Ruiz I, Bort M, Escorihuela M, Maqueda-Marcos S, Perez-Ramos S, Gago J, Nogales V, Espinosa-Bravo M, Peg V, Escrivá-de-Romaní S, Foradada L, Soucek L, Braña I, Galvao V, Martín-LLuesma S, Moessner E, Klein C, Garralda E, Saura C, Arribas J^*. Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors. Nat Commun 2024; 15(1): 9589.
• Herencia A, Llop-Guevara A^*, Staniszewska AD, Domènech-Vivó J, García-Galea E, Moles-Fernandez A, Pedretti F, Domènech H, Rodriguez O, Guzman M, Arenas EJ, Verdaguer H, Calero-Nieto FJ, Talbot S, Tobalina L, Leo E, Lau A, Nuciforo P, Dienstmann R, Macarulla T, Arribas J, Díez O, Gutierrez-Enriquez S, Forment JV, O'Connor MJ, Albertella M, Balmaña J^*, Serra V^*. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models. Genome Med 2024; 16(1): 107.
• Yáñez-Bartolomé M, Serra-Camprubi Q, Arenas EJ, Escorihuela M, Castet F, Fabregat-Franco C, Querol J, Arribas J, Peiró S, Macarulla T^*, Tian TV^*. Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models. Meth Mol Biol 2024; 2806: 139-151.
• Román M. Next generation CAR T cells targeting HER2-positive tumors. Universitat Autònoma de Barcelona. Director: Arribas J. Fecha lectura: 03/04/2024.
  Cites:0
• Chaib S, López-Domínguez JA^*, Lalinde M, Prats N, Marin I, Boix O, García-Garijo A, Meyer K, Muñoz MI, Aguilera M, Mateo L, Stephan-Otto C, Llanos S, Perez-Ramos S, Escorihuela M, Al-Shahrour F, Cash TP, Tchkonia T, Kirkland JL, Abad M, Gros A, Arribas J, Serrano M^*. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nat Cancer . 2024; 5(3): 448-462.